Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis

被引:1
作者
Zhang, Zhihong [1 ,2 ]
Wu, Guotai [2 ,3 ]
Yang, Jie [1 ,4 ]
Liu, Xuxia
Chen, Zhengjun [1 ]
Liu, Dongling [3 ]
Huang, Yan [5 ]
Yang, Fude [1 ]
Luo, Wenrong [6 ]
机构
[1] Gansu Univ Chinese Med, Sch Pharm, Lanzhou 730101, Peoples R China
[2] Gansu Key Lab Pharmacol & Toxicol Tradit Chinese M, Lanzhou 730000, Peoples R China
[3] Long Yao Ind Innovat Res Inst, Lanzhou 730000, Peoples R China
[4] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China
[5] Lanzhou Univ, Hosp 2, Dept Pharm, Lanzhou 730030, Peoples R China
[6] Gansu Prov Hosp Tradit Chinese Med, Lanzhou 730050, Peoples R China
关键词
Danggui-Baishao herb pair (DB); Hepatic fibrosis; Network pharmacology; Transcriptomics; Metabolomics; LIVER FIBROSIS;
D O I
10.1016/j.jep.2024.118834
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: The Danggui-Baishao herb pair (DB) is commonly used as Chinese herbal formulas for treating hepatic fibrosis (HF). However, there are few research on the combined application of the two drugs in treating HF, and the precise mechanisms and fundamental components of DB in addressing HF are still unclear. Aim of the study: The intention of this research is to identify the molecular foundation and functional targets of DB to elucidate the mechanisms for treating HF. Methods: The ingredients absorbed from DB in rat plasma were analyzed using UPLC-QE-MS. Therapeutic efficacy of DB in a rat model of CCl4-induced HF assessed using biochemical indices, pathological tissue observations, immunohistochemical and western blotting. An integrated strategy of transcriptomics, metabolomics, and network pharmacology was then utilized to explain the possible material basis and mechanisms of DB for treating HF. Western blotting was carried out to verify the critical mechanism. Results: DB reduced the level of liver function and inflammation related indicators in CCl4-induced HF (P < 0.05 or P < 0.01), as well as ameliorated pathological histological changes, and reduced the expressions of collagen type I (Col-I) and alpha-smooth muscle actin (alpha-SMA). Nineteen ingredients absorbed from DB were identified. Comprehensive investigations of transcriptomics, metabolomics, and network pharmacology revealed that DB modulated the PI3K/Akt/NF-kappa B signaling pathway to ameliorate fibrosis induced by CCl4 in HF rats. According to the molecular docking results, core tagets were highly favored by kaempferol, benzoylpaeoniflorin, albiflorin, paeoniflorin, and levistilide A. Conclusions: The possible mechanisms for DB treatment of HF include decreasing the activity of hepatic stellate cells (HSCs), decreasing collagen synthesis and deposition, attenuating the hepatic inflammatory response, inhibiting hepatocyte apoptosis, and increasing the level of niacinamide (NAM), thus exerting its anti-HF effect.
引用
收藏
页数:15
相关论文
共 45 条
  • [1] NAD+ Metabolism in Cardiac Health, Aging, and Disease
    Abdellatif, Mahmoud
    Sedej, Simon
    Kroemer, Guido
    [J]. CIRCULATION, 2021, 144 (22) : 1795 - 1817
  • [2] Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis
    Abraldes, JG
    Tarantino, I
    Turnes, J
    Garcia-Pagan, JC
    Rodés, J
    Bosch, J
    [J]. HEPATOLOGY, 2003, 37 (04) : 902 - 908
  • [3] Tamarix articulata Induced Prevention of Hepatotoxicity Effects of In Vivo Carbon Tetrachloride by Modulating Pro-Inflammatory Serum and Antioxidant Enzymes to Reverse the Liver Fibrosis
    Alnuqaydan, Abdullah M.
    Almutary, Abdulmajeed G.
    Alsahli, Mohammed A.
    Alnasser, Sulaiman
    Rah, Bilal
    [J]. ANTIOXIDANTS, 2022, 11 (09)
  • [4] [安振涛 An Zhentao], 2019, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V30, P1439
  • [5] Reversibility and heritability of liver fibrosis: Implications for research and therapy
    Atta, Hussein M.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (17) : 5138 - 5148
  • [6] Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis
    Baghaei, Kaveh
    Mazhari, Sogol
    Tokhanbigli, Samaneh
    Parsamanesh, Gilda
    Alavifard, Helia
    Schaafsma, Dedmer
    Ghavami, Saeid
    [J]. DRUG DISCOVERY TODAY, 2022, 27 (04) : 1044 - 1061
  • [7] Trolline Ameliorates Liver Fibrosis by Inhibiting the NF-κB Pathway, Promoting HSC Apoptosis and Suppressing Autophagy
    Bai, Facheng
    Huang, Quanfang
    Nie, Jinlan
    Lu, Shengjuan
    Lu, Chunyuan
    Zhu, Xunshuai
    Wang, Yuxin
    Zhuo, Lang
    Lu, Zhongpeng
    Lin, Xing
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 44 (02) : 436 - 446
  • [8] Animal and Organoid Models of Liver Fibrosis
    Bao, Yu-long
    Wang, Li
    Pan, Hai-ting
    Zhang, Tai-ran
    Chen, Ya-hong
    Xu, Shan-jing
    Mao, Xin-li
    Li, Shao-wei
    [J]. FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [9] Liver fibrosis: Pathophysiology and clinical implications
    Berumen, Jennifer
    Baglieri, Jacopo
    Kisseleva, Tatiana
    Mekeel, Kristin
    [J]. WIRES MECHANISMS OF DISEASE, 2021, 13 (01):
  • [10] The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease
    Brakedal, Brage
    Dolle, Christian
    Riemer, Frank
    Ma, Yilong
    Nido, Gonzalo S.
    Skeie, Geir Olve
    Craven, Alexander R.
    Schwarzlmuller, Thomas
    Brekke, Njal
    Diab, Joseph
    Sverkeli, Lars
    Skjeie, Vivian
    Varhaug, Kristin
    Tysnes, Ole-Bjorn
    Peng, Shichun
    Haugarvoll, Kristoffer
    Ziegler, Mathias
    Gruner, Renate
    Eidelberg, David
    Tzoulis, Charalampos
    [J]. CELL METABOLISM, 2022, 34 (03) : 396 - +